Trial Profile
Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Exemestane; Letrozole
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEO-EXCEL
- 12 Dec 2015 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
- 12 Dec 2015 Primary endpoint has been met (Objective clinical response), as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium